NASDAQ · VYNE
VYNE Therapeutics Inc.
$28.56$0.00 (0.0%)
VYNE Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.65% below the high.
Loading market information…
NASDAQ · ENSC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ensysce Biosciences, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ensysce Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$1.39+53.97% vs estimate | $1.31M+101.54% vs estimate |
|---|
| Q4 2024 | Mar 19, 2025 | -$2.90-5.84% vs estimate | $1.30M+430.61% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | $1.05+462.07% vs estimate | $3.41M+0.29% vs estimate |
|---|
KEEP COMPARING
$28.56$0.00 (0.0%)
VYNE Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.65% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$0.16-$0.00 (-2.42%)
AIM ImmunoTech Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.03% below the high.
$3.21+$0.17 (+5.59%)
Qualigen Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.56% below the high.
$2.12+$0.02 (+0.95%)
Xenetic Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.09% below the high.
$0.18-$0.00 (-2.67%)
KALA BIO, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$2.34-$0.30 (-11.36%)
Titan Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.55% below the high.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
